title: Repurposing of Aspirin and Ibuprofen as Candidate Anti-Cryptococcus Drugs.
abstract: The usage of fluconazole and amphotericin B in clinical settings is often limited by, among other things, drug resistance development and undesired side effects. Thus, there is a constant need to find new drugs to better manage fungal infections. Toward this end, the study described in this paper considered the repurposing of aspirin (acetylsalicylic acid) and ibuprofen as alternative drugs to control the growth of cryptococcal cells. In vitro susceptibility tests, including a checkerboard assay, were performed to assess the response of Cryptococcus neoformans and Cryptococcus gattii to the above-mentioned anti-inflammatory drugs. Next, the capacity of these two drugs to induce stress as well as their mode of action in the killing of cryptococcal cells was determined. The studied fungal strains revealed a response to both aspirin and ibuprofen that was dose dependent, with ibuprofen exerting greater antimicrobial action. More importantly, the MICs of these drugs did not negatively (i) affect growth or (ii) impair the functioning of macrophages; rather, they enhanced the ability of these immune cells to phagocytose cryptococcal cells. Ibuprofen was also shown to act in synergy with fluconazole and amphotericin B. The treatment of cryptococcal cells with aspirin or ibuprofen led to stress induction via activation of the high-osmolarity glycerol (HOG) pathway, and cell death was eventually achieved through reactive oxygen species (ROS)-mediated membrane damage. The presented data highlight the potential clinical application of aspirin and ibuprofen as candidate anti-Cryptococcus drugs.
authors.affiliation: Department of Microbial, Biochemical and Food Biotechnology, University of the Free State, Bloemfontein, South Africa.
authors.forename: Adepemi O
authors.initials: AO
authors.lastname: Ogundeji
authors.affiliation: Department of Microbial, Biochemical and Food Biotechnology, University of the Free State, Bloemfontein, South Africa.
authors.forename: Carolina H
authors.initials: CH
authors.lastname: Pohl
authors.affiliation: Department of Microbial, Biochemical and Food Biotechnology, University of the Free State, Bloemfontein, South Africa sebolaiom@ufs.ac.za.
authors.forename: Olihile M
authors.initials: OM
authors.lastname: Sebolai
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D003453:Cryptococcosis / Q000188:drug therapy*; D003454:Cryptococcus / Q000187:drug effects*; D058492:Drug Repositioning / Q000379:methods; D025141:Drug Resistance, Fungal / Q000187:drug effects; D015725:Fluconazole / Q000494:pharmacology; D007052:Ibuprofen / Q000494:pharmacology*; D051379:Mice; D000067996:RAW 264.7 Cells
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole; D001241:Aspirin; D007052:Ibuprofen